Skip to main content
Top
Published in: Pediatric Nephrology 2/2015

01-02-2015 | Original Article

Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children

Authors: Zhaoyang Peng, Jianhua Mao, Xuejun Chen, Fengqing Cai, Weizhong Gu, Haidong Fu, Huijun Shen, Jingjing Wang, Xia Jin, Xiujuan Zhu, Aimin Liu, Qiang Shu, Lizhong Du

Published in: Pediatric Nephrology | Issue 2/2015

Login to get access

Abstract

Background

Soluble urokinase plasminogen activator receptor (suPAR) has been regarded as a permeability factor in proteinuria, though its role in primary nephrotic syndrome remains to be elucidated further.

Methods

Plasma samples and clinical information from 176 children with primary nephrotic syndrome were collected and concentrations of suPAR were measured. We evaluated the correlation between suPAR concentrations and clinical features, and the value of the plasma suPAR level in predicting steroid-resistant nephrotic syndrome (SRNS).

Results

There is a significant difference in plasma suPAR concentration between SRNS and steroid-sensitive nephrotic syndrome (SSNS) groups (3,744.1 ± 2,226.0 vs. 2,153.5 ± 1,167.0, p < 0.05). The area under the curve (AUC) was 0.80, with p < 0.001 for the receiver operating characteristic (ROC) curve analysis using suPAR to predict SRNS. The suspicious range for predicting SRNS was estimated to be 1,907.0 pg/ml to 3,043.5 pg/ml (χ2 = 14.775, p = 0.001).

Conclusions

From ROC curve analysis, we demonstrated the significance of the suPAR level in predicting SRNS with a high specificity but low sensitivity. However, the clinical value of suPAR to predict steroid resistance and guide therapy remains to be investigated further.
Literature
2.
go back to reference D’Alessio S, Blasi F (2009) The urokinase receptor as an entertainer of signal transduction. Front Biosci 14:4575–4587CrossRef D’Alessio S, Blasi F (2009) The urokinase receptor as an entertainer of signal transduction. Front Biosci 14:4575–4587CrossRef
3.
go back to reference Smith HW, Marshall CJ (2010) Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 11:23–36PubMedCrossRef Smith HW, Marshall CJ (2010) Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 11:23–36PubMedCrossRef
4.
go back to reference Faul C, Asanuma K, Yanagida-Asanuma E, Kim K, Mundel P (2007) Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol 17:428–437PubMedCrossRef Faul C, Asanuma K, Yanagida-Asanuma E, Kim K, Mundel P (2007) Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol 17:428–437PubMedCrossRef
5.
go back to reference Wei C, Moller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J (2008) Modification of kidney barrier function by the urokinase receptor. Nat Med 14:55–63PubMedCrossRef Wei C, Moller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J (2008) Modification of kidney barrier function by the urokinase receptor. Nat Med 14:55–63PubMedCrossRef
6.
go back to reference Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J (2011) Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17:952–960PubMedCentralPubMedCrossRef Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J (2011) Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17:952–960PubMedCentralPubMedCrossRef
7.
go back to reference Kumagai T, Mouawad F, Takano T (2012) Pathogenesis of common glomerular diseases—role of the podocyte cytoskeleton. Cell Health Cytoskelet 2012:103–118 Kumagai T, Mouawad F, Takano T (2012) Pathogenesis of common glomerular diseases—role of the podocyte cytoskeleton. Cell Health Cytoskelet 2012:103–118
8.
go back to reference Zhang B, Xie S, Shi W, Yang Y (2012) Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria. Nephrol Dial Transplant 27:1746–1755PubMedCrossRef Zhang B, Xie S, Shi W, Yang Y (2012) Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria. Nephrol Dial Transplant 27:1746–1755PubMedCrossRef
9.
go back to reference Zhang B, Shi W, Ma J, Sloan A, Faul C, Wei C, Reiser J, Yang Y, Liu S, Wang W (2012) The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury. J Mol Med 90:1407–1420PubMedCentralPubMedCrossRef Zhang B, Shi W, Ma J, Sloan A, Faul C, Wei C, Reiser J, Yang Y, Liu S, Wang W (2012) The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury. J Mol Med 90:1407–1420PubMedCentralPubMedCrossRef
10.
go back to reference Cheng CC, Lee YF, Lan JL, Wu MJ, Hsieh TY, Lin NN, Wang JM, Chiu YT (2013) Mycophenolate mofetil alleviates lupus nephritis through urokinase receptor signaling in a mice model. Lupus 22:554–561PubMedCrossRef Cheng CC, Lee YF, Lan JL, Wu MJ, Hsieh TY, Lin NN, Wang JM, Chiu YT (2013) Mycophenolate mofetil alleviates lupus nephritis through urokinase receptor signaling in a mice model. Lupus 22:554–561PubMedCrossRef
11.
12.
go back to reference Naesens M, Meijers B, Sprangers B (2013) suPAR and FSGS: the gap between bench and bedside. Transplantation 96:368–369PubMedCrossRef Naesens M, Meijers B, Sprangers B (2013) suPAR and FSGS: the gap between bench and bedside. Transplantation 96:368–369PubMedCrossRef
13.
go back to reference Donadello K, Scolletta S, Taccone FS, Covajes C, Santonocito C, Cortes DO, Grazulyte D, Gottin L, Vincent JL (2013) Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients. J Crit Care 29:144–149PubMedCrossRef Donadello K, Scolletta S, Taccone FS, Covajes C, Santonocito C, Cortes DO, Grazulyte D, Gottin L, Vincent JL (2013) Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients. J Crit Care 29:144–149PubMedCrossRef
14.
go back to reference Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Hoyer-Hansen G, Ronne E, Dybkjaer E, Dano K, Brunner N (1997) ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 43:1868–1876PubMed Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Hoyer-Hansen G, Ronne E, Dybkjaer E, Dano K, Brunner N (1997) ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 43:1868–1876PubMed
15.
go back to reference Ostrowski SR, Katzenstein TL, Piironen T, Gerstoft J, Pedersen BK, Ullum H (2004) Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr 35:337–342PubMedCrossRef Ostrowski SR, Katzenstein TL, Piironen T, Gerstoft J, Pedersen BK, Ullum H (2004) Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr 35:337–342PubMedCrossRef
16.
go back to reference Perch M, Kofoed P, Fischer TK, Co F, Rombo L, Aaby P, Eugen-Olsen J (2004) Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection. Parasite Immunol 26:207–211PubMedCrossRef Perch M, Kofoed P, Fischer TK, Co F, Rombo L, Aaby P, Eugen-Olsen J (2004) Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection. Parasite Immunol 26:207–211PubMedCrossRef
17.
go back to reference Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, Aaby P, Gomes VF, Lisse I (2002) The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 6:686–692PubMed Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, Aaby P, Gomes VF, Lisse I (2002) The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 6:686–692PubMed
18.
go back to reference Katafuchi R, Kiyoshi Y, Oh Y, Uesugi N, Ikeda K, Yanase T, Fujimi S (1998) Glomerular score as a prognosticator in IgA nephropathy: its usefulness and limitation. Clin Nephrol 49:1–8PubMed Katafuchi R, Kiyoshi Y, Oh Y, Uesugi N, Ikeda K, Yanase T, Fujimi S (1998) Glomerular score as a prognosticator in IgA nephropathy: its usefulness and limitation. Clin Nephrol 49:1–8PubMed
19.
go back to reference Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr (1997) Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 8:769–776PubMed Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr (1997) Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 8:769–776PubMed
20.
go back to reference Wong W (2007) Idiopathic nephrotic syndrome in New Zealand children, demographic, clinical features, initial management and outcome after 12-month follow-up: results of a 3-year national surveillance study. J Paediatr Child Health 43:337–341PubMedCrossRef Wong W (2007) Idiopathic nephrotic syndrome in New Zealand children, demographic, clinical features, initial management and outcome after 12-month follow-up: results of a 3-year national surveillance study. J Paediatr Child Health 43:337–341PubMedCrossRef
21.
go back to reference Mekahli D, Liutkus A, Ranchin B, Yu A, Bessenay L, Girardin E, van Damme-Lombaerts R, Palcoux J-B, Cachat F, Lavocat M-P, Bourdat-Michel G, Nobili F, Cochat P (2009) Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study. Pediatr Nephrol 24:1525–1532PubMedCrossRef Mekahli D, Liutkus A, Ranchin B, Yu A, Bessenay L, Girardin E, van Damme-Lombaerts R, Palcoux J-B, Cachat F, Lavocat M-P, Bourdat-Michel G, Nobili F, Cochat P (2009) Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study. Pediatr Nephrol 24:1525–1532PubMedCrossRef
22.
go back to reference Wang W, Xia Y, Mao J, Chen Y, Wang D, Shen H, Fu H, Du L, Liu A (2012) Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndrome. Pediatr Nephrol 27:2073–2079PubMedCrossRef Wang W, Xia Y, Mao J, Chen Y, Wang D, Shen H, Fu H, Du L, Liu A (2012) Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndrome. Pediatr Nephrol 27:2073–2079PubMedCrossRef
23.
go back to reference Yao SH, Mao JH, Xia YH, Wang DY, Chen YF, Fang CQ, Liu AM, Du LZ (2011) Clinical application of tacrolimus with low-dose prednisone in 21 children with steroid-resistant nephrotic syndrome. Chin J Pediatr 49:825–828 Yao SH, Mao JH, Xia YH, Wang DY, Chen YF, Fang CQ, Liu AM, Du LZ (2011) Clinical application of tacrolimus with low-dose prednisone in 21 children with steroid-resistant nephrotic syndrome. Chin J Pediatr 49:825–828
24.
go back to reference Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, McMahan JL, Radeva M, Heil KM, Trautmann A, Anarat A, Emre S, Ghiggeri GM, Ozaltin F, Haffner D, Gipson DS, Kaskel F, Fischer DC, Schaefer F, Reiser J, PodoNet CFCS (2012) Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 23:2051–2059PubMedCentralPubMedCrossRef Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, McMahan JL, Radeva M, Heil KM, Trautmann A, Anarat A, Emre S, Ghiggeri GM, Ozaltin F, Haffner D, Gipson DS, Kaskel F, Fischer DC, Schaefer F, Reiser J, PodoNet CFCS (2012) Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 23:2051–2059PubMedCentralPubMedCrossRef
25.
go back to reference Kemper MJ, Wei C, Reiser J (2013) Transmission of glomerular permeability factor soluble urokinase plasminogen activator receptor (suPAR) from a mother to child. Am J Kidney Dis 61:9CrossRef Kemper MJ, Wei C, Reiser J (2013) Transmission of glomerular permeability factor soluble urokinase plasminogen activator receptor (suPAR) from a mother to child. Am J Kidney Dis 61:9CrossRef
26.
go back to reference Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ, Chu R, Chen Y, Zhao MH (2013) Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int 84:366–372PubMedCrossRef Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ, Chu R, Chen Y, Zhao MH (2013) Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int 84:366–372PubMedCrossRef
27.
go back to reference Franco Palacios CR, Lieske JC, Wadei HM, Rule AD, Fervenza FC, Voskoboev N, Garovic VD, Zand L, Stegall MD, Cosio FG, Amer H (2013) Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation 96:394–399PubMedCrossRef Franco Palacios CR, Lieske JC, Wadei HM, Rule AD, Fervenza FC, Voskoboev N, Garovic VD, Zand L, Stegall MD, Cosio FG, Amer H (2013) Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation 96:394–399PubMedCrossRef
28.
go back to reference Meijers B, Maas RJH, Sprangers B, Claes K, Poesen R, Bammens B, Naesens M, Deegens JKJ, Dietrich R, Storr M, Wetzels JFM, Evenepoel P, Kuypers D (2014) The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int 85:636–640PubMedCrossRef Meijers B, Maas RJH, Sprangers B, Claes K, Poesen R, Bammens B, Naesens M, Deegens JKJ, Dietrich R, Storr M, Wetzels JFM, Evenepoel P, Kuypers D (2014) The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int 85:636–640PubMedCrossRef
29.
go back to reference Bock ME, Price HE, Gallon L, Langman CB (2013) Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report. Clin J Am Soc Nephrol 8:1304–1311PubMedCentralPubMedCrossRef Bock ME, Price HE, Gallon L, Langman CB (2013) Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report. Clin J Am Soc Nephrol 8:1304–1311PubMedCentralPubMedCrossRef
30.
go back to reference Sinha A, Bajpai J, Saini S, Bhatia D, Gupta A, Puraswani M, Dinda AK, Agarwal SK, Sopory S, Pandey RM, Hari P, Bagga A (2014) Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children. Kidney Int 85:649–658PubMedCrossRef Sinha A, Bajpai J, Saini S, Bhatia D, Gupta A, Puraswani M, Dinda AK, Agarwal SK, Sopory S, Pandey RM, Hari P, Bagga A (2014) Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children. Kidney Int 85:649–658PubMedCrossRef
31.
go back to reference Wada T, Nangaku M, Maruyama S, Imai E, Shoji K, Kato S, Endo T, Muso E, Kamata K, Yokoyama H, Fujimoto K, Obata Y, Nishino T, Kato H, Uchida S, Sasatomi Y, Saito T, Matsuo S (2014) A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease. Kidney Int 85:641–648PubMedCrossRef Wada T, Nangaku M, Maruyama S, Imai E, Shoji K, Kato S, Endo T, Muso E, Kamata K, Yokoyama H, Fujimoto K, Obata Y, Nishino T, Kato H, Uchida S, Sasatomi Y, Saito T, Matsuo S (2014) A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease. Kidney Int 85:641–648PubMedCrossRef
32.
go back to reference Maas RJ, Deegens JK, Wetzels JF (2013) Serum suPAR in patients with FSGS: trash or treasure? Pediatr Nephrol 28:1041–1048PubMedCrossRef Maas RJ, Deegens JK, Wetzels JF (2013) Serum suPAR in patients with FSGS: trash or treasure? Pediatr Nephrol 28:1041–1048PubMedCrossRef
Metadata
Title
Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children
Authors
Zhaoyang Peng
Jianhua Mao
Xuejun Chen
Fengqing Cai
Weizhong Gu
Haidong Fu
Huijun Shen
Jingjing Wang
Xia Jin
Xiujuan Zhu
Aimin Liu
Qiang Shu
Lizhong Du
Publication date
01-02-2015
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 2/2015
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-014-2892-6

Other articles of this Issue 2/2015

Pediatric Nephrology 2/2015 Go to the issue